10.05.2016 Views

Final Program

h6okmgq

h6okmgq

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

MONDAY • MAY 16 137<br />

B5<br />

BASIC • TRANSLATIONAL<br />

BASIC SCIENCE CORE<br />

CME Credits Available: 2.0<br />

HARNESSING BREAKTHROUGHS IN CRISPR GENE<br />

EDITING TECHNOLOGY FOR RESEARCH AND<br />

THERAPY<br />

Assemblies on Respiratory Cell and Molecular Biology; Allergy,<br />

Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary<br />

Infections; Respiratory Structure and Function; Thoracic Oncology<br />

9:00 a.m. - 11:00 a.m. MOSCONE CENTER<br />

Room 2009/2011 (West Building, Level 2)<br />

Target Audience<br />

Basic and translational researchers seeking to understand the most important<br />

advance in biotechnology in the last decade and clinical investigators and<br />

clinicians interested in learning more about this technology that is poised to<br />

move into clinical application in the coming decade.<br />

Objectives<br />

At the conclusion of this session, the participant will be able to:<br />

• learn new findings about the CRISPR system functions and how it can be<br />

adapted to edit human and other animal genomes;<br />

• improve lung research by learning new strategies for selectively turning<br />

genes on and off, creating lung cancer models, performing genome-wide<br />

screens, and imaging the genome;<br />

• contribute to conversations that will shape scientific and ethical approaches<br />

to the use of CRISPR technology to treat human disease.<br />

The development of the CRISPR system for efficient and selective editing of the<br />

human genome represents the most important scientific breakthrough of the<br />

past decade. CRISPR-based systems are already being widely used for<br />

inactivating or repairing individual genes in human cells and animal models and<br />

for genome-wide studies of the functions of coding and non-coding RNAs. This<br />

session will introduce the basic CRISPR/Cas9 system, explain how this<br />

technology is being modified to allow selective inactivation, activation, and live<br />

imaging of the genome, and illustrate how the technology can be applied to<br />

study and treat lung diseases, including cancer.<br />

Chairing: D. Erle, MD, San Francisco, CA<br />

S. Albelda, MD, Philadephia, PA<br />

N. Chandel, PhD, Chicago, IL<br />

9:00 CRISPR: From Biology to Transformative Technology<br />

J. Corn, PhD, Berkeley, CA<br />

9:30 Genome-Scale CRISPR-Mediated Control of Gene Repression<br />

and Activation<br />

J. Weissman, PhD, San Francisco, CA<br />

10:00 Dissecting the Role of Oxidative Homeostasis in Lung Cancer<br />

Using CRISPR/Cas9 Genome Engineering<br />

T. Papagiannakopoulos, PhD, New York, NY<br />

10:30 CRISPR Tools for Complex Transcription Control and<br />

Functional Study<br />

S. Qi, PhD, Stanford, CA<br />

This session and the International Conference are supported by an educational grant from<br />

AstraZeneca LP.<br />

All CME sessions have been planned and implemented in accordance with the Essential<br />

Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)<br />

and are free of the control of commercial interests.<br />

B6<br />

BEHAVIORAL • CLINICAL<br />

SCIENTIFIC SYMPOSIUM<br />

CME Credits Available: 2.0<br />

BUILDING E-BRIDGES: TOOLS AT OUR FINGERTIPS<br />

FOR ENHANCING COLLABORATIVE CARE<br />

Assemblies on Behavioral Science and Health Services Research;<br />

Clinical Problems; Critical Care; Nursing; Thoracic Oncology<br />

9:00 a.m. - 11:00 a.m. MOSCONE CENTER<br />

Room 303/305 (South Building, Esplanade Level)<br />

Target Audience<br />

Clinicians and scientists seeking to understand developments in shared<br />

decision-making and to explore cutting edge tools aimed at advancing<br />

interdisciplinary, patient centered collaboration across pulmonary and critical care.<br />

Objectives<br />

At the conclusion of this session, the participant will be able to:<br />

• present new findings about the complexity of shared decision-making to<br />

enhance patient-centered care;<br />

• apply novel, innovative tools to enrich risk communication and improve the<br />

quality of life and health of patients;<br />

• evaluate future directions in and barriers to collaborative, personalized care.<br />

For most medical decisions, multiple options are available with each choice having<br />

its own list of benefits and harms. Decisions inconsistent with patient preferences<br />

may have unintended consequences to both patients and the health system. Shared<br />

decision-making provides a model for personalized medicine to enhance<br />

patient-centered care. This session will allow leading experts to discuss: (1) how<br />

traditional communication has failed and why shared decision-making has evolved;<br />

(2) the complexity of the decision-making process; (3) what tools are available,<br />

across pulmonary and critical care, to enhance communication; (4) what future<br />

directions and barriers may lie ahead in patient-centered risk communication.<br />

Chairing: T.S. Valley, MD, Ann Arbor, MI<br />

R.S. Wiener, MD, MPH, Boston, MA<br />

C.E. Cox, MD, MPH, Durham, NC<br />

9:00 A Patient’s Perspective<br />

K. Erickson, Coral Gables, FL<br />

9:05 Helping Me Help You: Making the Right Decision for Different<br />

Patients<br />

T.S. Valley, MD, Ann Arbor, MI<br />

9:23 So You’re Telling Me There’s a Chance? Theories to Improve<br />

Risk Communication<br />

J.L. Hart, MD, Philadelphia, PA<br />

MONDAY MORNING<br />

ATS 2016 • San Francisco

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!